Skip to main content

Cystografin Dilute

Generic: diatrizoate meglumine

Verified·Apr 23, 2026
Manufacturer
Bracco
NDC
0270-1410
Route
INTRAVESICAL
ICD-10 indication
N13.70

Affordability Check

How much will you actually pay for Cystografin Dilute?

In 30 seconds, see every legitimate way to afford Cystografin Dilute — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About Cystografin Dilute

What is this medication?

Cystografin Dilute is a prescription radiopaque contrast agent used during diagnostic imaging of the urinary tract. It contains diatrizoate meglumine, which is an organic iodine compound that helps doctors see internal structures more clearly. This specific medication is intended for retrograde cystourethrography, a procedure where the fluid is administered through a catheter into the bladder to evaluate the lower urinary system using X-ray technology.

During the procedure, the contrast medium fills the bladder and urethra to highlight potential issues such as blockages, stones, or abnormal growths. It is frequently used to diagnose vesicoureteral reflux, a condition where urine travels the wrong way from the bladder back toward the kidneys. The iodine in the solution effectively blocks X-rays, creating a sharp visual contrast that allows medical professionals to identify anatomical problems that are not visible on standard X-ray films.

Copay & patient assistance

Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program for more details.

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Prescribing information

From the FDA-approved label for Cystografin Dilute. Official source: DailyMed (NLM) · Label effective Nov 23, 2025

Indications and usage
INDICATION Cystografin Dilute is indicated for retrograde cystourethrography.
Dosage and administration
DOSAGE AND ADMINISTRATION Preparation of the patient: Appropriate preparation is desirable for optimal results. A laxative the night before the examination and a low residue diet the day before the procedure are recommended. Dosage: The dose for retrograde use in cystography and voiding cystourethrography ranges from 25 to 300 mL depending on the age of the patient and the degree of bladder irritability; amounts greater than 300 mL may be used if the bladder capacity allows. Best results are obtained when the bladder is filled with the contrast agent. Administration: After sterile catheterization, the bladder should be filled to capacity with Cystografin Dilute using a suitable sterile administration set. Care should be taken to avoid using excessive pressure. The presence of bladder discomfort or reflux and/or spontaneous voiding usually indicates that the bladder is full. Radiography: The commonly employed radiographic techniques should be used. A scout film is recommended before the contrast agent is administered.
Contraindications
CONTRAINDICATIONS This preparation is contraindicated in patients with a hypersensitivity to salts of diatrizoic acid.
Warnings
WARNINGS Severe sensitivity reactions are more likely to occur in patients with a personaI or family history of bronchial asthma, significant allergies, or previous reactions to contrast agents. A history of sensitivity to iodine per se or to other contrast agents is not an absolute contraindication to the use of diatrizoate meglumine, but calls for extreme caution in administration.
Adverse reactions
ADVERSE REACTIONS Retrograde genitourinary procedures may cause such complications as hematuria, perforation of the urethra or bladder, introduction of infection into the genitourinary tract, and oliguria or anuria. If intravasation of this drug occurs, the reactions which may be associated with intravenous administration may possibly be encountered. Hypersensitivity or anaphylactoid reactions may occur. Severe reactions may be manifested by edema of the face and glottis, respiratory distress, convulsions or shock; such reactions may prove fatal unless promptly controlled by such emergency measures as maintenance of a clear airway and immediate use of oxygen and resuscitative drugs. Endocrine: Thyroid function tests indicative of hypothyroidism or transient thyroid suppression have been uncommonly reported following iodinated contrast media administration to adult and pediatric patients, including infants. Some patients were treated for hypothyroidism.

Label text is reproduced as-is from the FDA-approved label. We do not paraphrase, summarize, or omit. Content above is for informational purposes only and is not medical advice. Always consult your prescribing clinician or pharmacist before making decisions about your medication.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Prior authorization & coverage

PayerPAStep therapyCopay tier

Medicare Part D

Related drugs

How this page is sourced

  • Drug identity verified against openFDA NDC Directory.
  • Label text (when shown) originates from NLM DailyMed.
  • Copay and assistance URLs verified periodically; if you hit a broken link, tell us.